Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas

Gaetano Corazzelli, Ferdinando Frigeri, Manuela Arcamone, Luigi Aloj, Gaetana Capobianco, Cristina Becchimanzi, Emanuela Morelli, Francesco Volzone, Gianpaolo Marcacci, Filippo Russo, Rosaria De Filippi, Secondo Lastoria, Antonio Pinto

Research output: Contribution to journalArticlepeer-review

Abstract

Patients with recurring T-cell non-Hodgkin lymphoma (T-NHL) are incurable and candidate for investigational agents. Here, we report on five patients with T-NHL refractory to multiple chemotherapy lines, including in all cases alkylators and gemcitabine, who received the third-generation chloroethylnitrosourea fotemustine at a dose of 120mg/m 2 every 21d, up to eight courses. Median actual dose intensity was 79%; toxicity was manageable and mainly hematological. One complete remission, one partial remission, two protracted disease stabilization, and one transient, minor response were achieved. Time to progression ranged from 48 to 240+d. This is the first evidence ever reporting the activity of fotemustine in end-stage T-NHL. Formal studies with this agent are warranted in T-cell malignancies.

Original languageEnglish
Pages (from-to)547-553
Number of pages7
JournalEuropean Journal of Haematology
Volume87
Issue number6
DOIs
Publication statusPublished - Dec 2011

Keywords

  • Fotemustine
  • Nitrosourea
  • Salvage therapy
  • Sezary syndrome
  • T-cell lymphomas

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas'. Together they form a unique fingerprint.

Cite this